

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[Docket No. 2006N-0202]

Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002**AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Jonna Capezuto, Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of December 20, 2006 (71 FR 76344), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0520. The approval expires on May 31, 2010. A copy of the supporting statement for this information collection is available on the Internet at <http://www.fda.gov/ohrms/dockets>.

Dated: May 29, 2007.

Jeffrey Shuren,*Assistant Commissioner for Policy.*

[FR Doc. E7-10785 Filed 6-4-07; 8:45 am]

BILLING CODE 4160-01-S**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Food and Drug Administration****Request for Nominations for Voting Members on a Public Advisory Committee; Risk Communication Advisory Committee****AGENCY:** Food and Drug Administration, HHS.**ACTION:** Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the Risk Communication Advisory Committee in the Office of Planning, Office of the Commissioner. Elsewhere in this issue of the **Federal Register**, FDA is publishing a document announcing the establishment of this committee.

FDA has special interest in ensuring that women, minority groups, and individuals with disabilities are adequately represented on advisory committees and, therefore, encourages nominations of qualified candidates from these groups.

DATES: Nominations received on or before July 20, 2007 will be given first consideration for membership on the Risk Communication Advisory Committee. Nominations received after July 20, 2007 will be considered for nomination to the Risk Communication Advisory Committee should nominees still be needed.

ADDRESSES: All nominations for membership should be sent to the contact person listed in the **FOR FURTHER INFORMATION CONTACT** section of this document.

FOR FURTHER INFORMATION CONTACT: Regarding all nomination questions for membership, the primary contact is Lee Zwanziger, Office of Planning, Office of the Commissioner (HFP-1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-2895, FAX: 301-827-5260, e-mail: rcac@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations for voting members on the Risk Communication Advisory Committee.

I. Function of the Risk Communication Advisory Committee

The committee advises the Commissioner of Food and Drugs on strategies and programs designed to communicate with the public about both the risks and benefits of FDA-regulated products so as to facilitate optimal use of these products. The

committee also reviews and evaluates research relevant to such communication to the public by both FDA and other entities. It also facilitates interactively sharing risk and benefit information with the public to enable people to make informed independent judgments about use of FDA-regulated products.

II. Criteria for Voting Members*A. Experts*

Persons nominated for membership must have scientific expertise or extensive experience in one or more of the following fields: Risk communication; risk perception; social marketing; communications; cognitive, social, health, behavioral, or other relevant specialties of psychology or sociology; decision analysis; qualitative or quantitative research methodology; health literacy; cultural competency; journalism; and/or biomedical ethics.

B. Public Members

Persons nominated for membership on the committee to provide a perspective from real-world experience on the communication needs of the various groups who use FDA-regulated products must have the following skills: (1) Ability to communicate the interests and perspectives of consumers, patients, patient-caregivers, or health professionals; (2) ability to discuss benefits and risks; and (3) ability to understand the results of research studies. In addition, preference will be given to nominees who have one or more of the following qualifications: (1) Ability to analyze technical data; (2) understanding of research design; (3) ability to disseminate information about the advisory committee experience to the community; and (4) ties to a consumer, patient, and/or community-based organization. As a member of the Risk Communication Advisory Committee, these individuals will serve in their individual capacities. However, we expect that they can also serve as conduits between FDA and the general public. Nominated individuals may include patients and patients' family members, health professionals, communicators in health, medicine, and science, and persons affiliated with consumer, specific disease, or patient safety advocacy groups.

III. Nomination Procedures

Any interested person may nominate one or more qualified persons for membership on the advisory committee. Self-nominations are also accepted. Nominations must include a current resume or curriculum vitae of each